A proposed US-funded hepatitis B vaccine trial in Guinea-Bissau will not proceed because it lacked government approval, a researcher involved told Al Jazeera. The BBC also reported its cancellation after an ethics dispute over delaying a recommended birth dose for thousands of newborns.

The study never began, according to University of Southern Denmark dean Jakob Grauslund, who told the BBC that no babies were enrolled or vaccinated through the research. Police seized vaccines from the Bandim Health Project’s facilities in October; authorities said they were investigating compliance with national safety requirements.

The planned study would randomly assign about 14,000 babies to vaccination at birth or six weeks later, then track health outcomes for five years, Al Jazeera reported. The US Centers for Disease Control and Prevention awarded the university $1.6 million in December 2025, according to the BBC.

Bandim researchers said their question concerned possible broader health effects of birth-dose vaccination, not whether the vaccine prevents hepatitis B. They argued that Guinea-Bissau’s existing six-week schedule offered an opportunity to compare outcomes before routine birth doses were introduced.

Critics said that design would deny some newborns established protection. Walter Kazadi Mulombo, the World Health Organization’s representative in Guinea-Bissau, told the BBC that withholding a proven intervention was unethical. Babies can acquire hepatitis B during childbirth, and infection in infancy carries a high risk of becoming chronic, potentially causing liver damage and cancer.

Approval remained contested. The university said a revised protocol had received local ethical clearance, but Health Minister Quinhin Nantote said in October that the government’s January suspension remained in force. Al Jazeera reported that officials had not commented on the researcher’s subsequent announcement that the trial would not go ahead.